Biomarkers for risk assessment and treatment monitoring in heart failure patients who receive B-type natriuretic peptide guided therapy

The present invention relates to a method for identifying a patient who is eligible to an intensification of heart failure therapy. Furthermore, the present invention relates to a method for optimizing BNP-type peptide guided heart failure therapy. The methods are based on the measurement of the lev...

Full description

Saved in:
Bibliographic Details
Main Authors UBBY, JOHAN, BLOCK, DIRK, WIENHUES-THELEN, URSULA-HENRIKE, SANDERS-VAN WIJK, SANDRA, ZAUGG, CHRISTIAN, DIETERLE, THOMAS, MITCHELL, CHERYL, BRUNNER, HANSPETER
Format Patent
LanguageEnglish
French
German
Published 29.07.2015
Subjects
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
PHYSICS
TESTING
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a method for identifying a patient who is eligible to an intensification of heart failure therapy. Furthermore, the present invention relates to a method for optimizing BNP-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives BNP-type peptide guided heart failure therapy. Further envisaged by the present invention are kits and devices adapted to carry out the present invention. The at least one marker is selected from the group consisting of creatinine, urea, sodium, glucose, HbAlc (glycated hemoglobin), hemoglobin, and hematocrit. Further markers are disclosed.
Bibliography:Application Number: EP20140152777